You are here
HC Surgical and Heliconia end S$5m investment agreement
HC Surgical Specialists on Friday said that it and Vanda 1 Investments, managed by Temasek's Heliconia Capital Management, have entered into an early redemption and termination deed for a S$5 million convertible bond that Vanda had subscribed for to help fund the company's regional business expansion.
Both sides on Friday mutually agreed to the early redemption of the convertible bond, the cancellation of the option for Vanda 1 Investments to invest a further S$5 million, and have agreed to terminate the investment agreement.
HC Surgical said the redemption allows the company to reduce its financing cost.
It will redeem the convertible bond at a redemption price equal to the aggregate principal amount of the convertible bond, together with unpaid interest accrued at a rate of 5.5 per cent per annum up to the early redemption date.
Based on an early redemption date of April 27, 2020, the redemption price is about S$5.2 million, HC Surgical said. It plans to fund this through a combination of bank borrowings and internal cash resources.
"Notwithstanding the redemption of the convertible bond, the directors are of the opinion that after taking into consideration the group’s present banking facilities, the working capital available to the group is sufficient to meet its present requirements."
The deed is not expected to have any material impact on the group's consolidated earnings per share or net tangible assets per share for the current financial year ending May 31, 2020, it addded.
Under the investment agreement, Heliconia was to have invested S$5 million via a three-year 5.5 per cent convertible bond that is convertible at the option of Heliconia into new ordinary shares of HC Surgical at a conversion price of S$0.5361 per conversion share. In addition, Heliconia will receive a three-year option to subscribe for up to S$5 million of new shares of HC Surgical, at an exercise price of S$0.62 per share.
The Catalist-listed firm’s shares was hammered after news that a doctor at its subsidiary had lost a defamation suit over claims that he was colluding with a fellow specialist for sex with patients.